Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1998-4-23
|
| pubmed:abstractText |
The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled corticosteroids (ICS). In a randomized, double-blind, placebo-controlled, cross-over study, a challenge test with histamine (provocative concentration of histamine producing a 20% fall in forced expiratory volume in one second (FEV1) (PC20,Hist)) and with ultrasonically nebulized distilled water (UNDW) (provocative dose of UNDW producing a 20% fall in FEV1 (PD20,UNDW)) was performed in seven patients with asthma after intake of either 400 mg zileuton or placebo. All patients (mean age 33 yrs, mean FEV1 111% of predicted) had marked BHR, as indicated by a mean PD20,UNDW of 4.74 mL under treatment for at least 6 months with up to 800 microg ICS (mean 536 microg daily). On four different occasions, separated by at least 5 days, two UNDW and two histamine challenge tests were performed in random order 3 h after a morning dose of either zileuton or placebo. Neither zileuton nor placebo changed baseline airway calibre prior to provocation. Zileuton increased PC20,Hist from 0.99 to 5.64 mg x mL(-1) (2.1 doubling doses; p<0.03 compared to placebo), and increased PD20,UNDW from 3.10 to 9.31 mL (1.3 doubling doses; p<0.05 compared to placebo). In conclusion, a single dose of 400 mg zileuton attenuates bronchial hyperresponsiveness to histamine and ultrasonically nebulized distilled water in asthmatic patients with marked bronchial hyperresponsiveness during treatment with inhaled corticosteroids.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyurea,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Water,
http://linkedlifedata.com/resource/pubmed/chemical/zileuton
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0903-1936
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2749-53
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9493655-Administration, Inhalation,
pubmed-meshheading:9493655-Adrenal Cortex Hormones,
pubmed-meshheading:9493655-Adult,
pubmed-meshheading:9493655-Asthma,
pubmed-meshheading:9493655-Bronchial Hyperreactivity,
pubmed-meshheading:9493655-Bronchial Provocation Tests,
pubmed-meshheading:9493655-Cross-Over Studies,
pubmed-meshheading:9493655-Dose-Response Relationship, Drug,
pubmed-meshheading:9493655-Double-Blind Method,
pubmed-meshheading:9493655-Drug Interactions,
pubmed-meshheading:9493655-Female,
pubmed-meshheading:9493655-Histamine,
pubmed-meshheading:9493655-Humans,
pubmed-meshheading:9493655-Hydroxyurea,
pubmed-meshheading:9493655-Lipoxygenase Inhibitors,
pubmed-meshheading:9493655-Male,
pubmed-meshheading:9493655-Middle Aged,
pubmed-meshheading:9493655-Reference Values,
pubmed-meshheading:9493655-Respiratory Function Tests,
pubmed-meshheading:9493655-Sensitivity and Specificity,
pubmed-meshheading:9493655-Water
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
|
| pubmed:affiliation |
Dept of Pulmonary Diseases, Academic Hospital Nijmegen, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|